PB->NA

NHS

National Research Ethics Service

South East Research Ethics Committee
South East Coast Strategic Health Authority
Preston Hall
Aylesford
Kent
ME20 7NJ

Telephone: 01622 713048
Facsimile: 01622 885966

24 MAY 2010

20 May 2010

Professor Philip M. W. Bath
Professor of Stroke Medicine
University of Nottingham
Division of Stroke Medicine - Research Dept
Clinical Sciences Building
City Hospital Campus
Hucknall Road
Nottingham
NG5 1PB

Dear Professor Bath

Study Title:	**Safety and tolerability of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke: a randomised controlled trial**
REC reference number:	**08/H1102/112**
Protocol number:	**1.1**
EudraCT number:	**2007-006749-42**
Amendment number:	**SA02/10 11 May 2010**
Amendment date:	**11 May 2010**

Thank you for submitting the above amendment, which was received on 12 May 2010.

Research Site	Principal Investigator / Local Collaborator
Northumbria Healthcare NHS Foundation Trust, Wansbeck General Hospital, Woodhorn Lane, Ashington, NE63 9JJ	Christopher Price
North Tyneside General Hospital, Rake Lane, North Shields, NE29 8NH	Christopher Price
Wishaw General Hospital, 50 Netherton Street, WIshaw, ML2 0DP	Martin Whitehead
Poole Hospital NHS Foundation Trust, Consultant in Geriatric & Stroke Medicine, Longfleet Road, Poole, Dorset, BH15 2NG	Suzane Ragab
Whiston Hospital, Warrington Road, Prescot, L35 5DR	Sanjeevikumar Meenakshisundaram (replacing Dr Gowda)

The amendment relates solely to the addition of new site(s) and/or investigator(s) within the National Health Service (NHS) or Health and Social Care (HSC) in Northern Ireland. The site-specific assessment for the site(s) will therefore form part of the research governance review. The Site-Specific Information (SSI) Form for the site should be included with the application for R&D approval.

On behalf of the Committee, I am pleased to confirm the extension of the favourable opinion to the new site(s) and/or investigator(s), subject to management permission being given by the relevant NHS/HSC R&D office(s) prior to the study starting at the site.

Statement of compliance

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.

The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees (July 2001) and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

08/H1102/112	**Please quote this number on all correspondence**

Yours sincerely

Sharon Busbridge
Assistant Committee Co-ordinator

Copy to: *Mr Paul Cartledge*
Clinical Trials Unit, MHRA